Q3 Earnings Estimate for BNGO Issued By Maxim Group

Bionano Genomics, Inc. (NASDAQ:BNGO) – Equities research analysts at Maxim Group issued their Q3 2026 earnings per share (EPS) estimates for shares of Bionano Genomics in a research note issued on Friday, November 6th. Maxim Group analyst M. Okunewitch anticipates that the company will post earnings per share of ($0.45) for the quarter. The consensus estimate for Bionano Genomics’ current full-year earnings is ($2.49) per share.

Bionano Genomics (NASDAQ:BNGO) last released its earnings results on Monday, August 10th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.03. Bionano Genomics had a negative return on equity of 78.78% and a negative net margin of 106.58%. The business had revenue of ($6.67) million for the quarter, compared to analyst estimates of $7.55 million.

A number of other research firms have also weighed in on BNGO. Wall Street Zen upgraded shares of Bionano Genomics to a “hold” rating in a research report on Saturday, September 26th. Weiss Ratings upgraded shares of Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $6.00.

Bionano Genomics Price Performance

Bionano Genomics stock opened at $1.16 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.96. The business has a 50 day simple moving average of $1.37 and a 200-day simple moving average of $1.23. Bionano Genomics has a 12 month low of $1.00 and a 12 month high of $2.23. The stock has a market capitalization of $16.22 million, a PE ratio of -0.38 and a beta of 1.73.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BNGO. Renaissance Technologies LLC lifted its stake in shares of Bionano Genomics by 31.6% in the first quarter. Renaissance Technologies LLC now owns 48,700 shares of the company’s stock valued at $57,000 after purchasing an additional 11,700 shares during the period. Carret Asset Management LLC grew its position in Bionano Genomics by 8.4% during the third quarter. Carret Asset Management LLC now owns 135,545 shares of the company’s stock worth $211,000 after buying an additional 10,545 shares during the period. GSA Capital Partners LLP acquired a new position in Bionano Genomics during the second quarter worth about $170,000. Finally, AIGH Capital Management LLC acquired a new position in Bionano Genomics during the third quarter worth about $1,817,000. Institutional investors and hedge funds own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc is a life sciences company that develops genomic analysis tools designed to help researchers and clinicians detect large-scale structural variations in DNA. Its technology is intended to complement or extend conventional sequencing and cytogenetic methods by providing information about changes in genome structure, including deletions, duplications, inversions and translocations.

The company’s principal platform is the Saphyr system, an optical genome mapping solution that analyzes ultra-high-molecular-weight DNA.